EVRY, France--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced the publication of a study in Clinical Cancer Research which reports on the ability of the microRNA (miRNA) miR-31-3p to predict progression-free survival in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) antibodies.
Help employers find you! Check out all the jobs and post your resume.
